New standards of care for treatment of diffuse large B-cell lymphoma

Chathuri Abeyakoon; Gareth P Gregory

doi:10.1111/bjh.19295

New standards of care for treatment of diffuse large B-cell lymphoma

Br J Haematol. 2024 Apr;204(4):1132-1134. doi: 10.1111/bjh.19295. Epub 2024 Jan 22.

Authors

Chathuri Abeyakoon^{1

2

3}, Gareth P Gregory^{1

2}

Affiliations

¹ Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
² Monash Haematology, Monash Health, Clayton, Victoria, Australia.
³ Department of Medical Oncology and Haematology, Princess Margaret Hospital, Toronto, Ontario, Canada.

PMID: 38251726
DOI: 10.1111/bjh.19295

Abstract

Treatment of newly diagnosed diffuse large B-cell lymphoma with rituximab and CHOP (R-CHOP) has been largely unchanged for the last two decades. The Guideline by Fox et al. provides new evidence-based therapeutic strategies informed by positive results of randomised clinical trials. Commentary on: Fox et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol 2024; 204:1178-1192.

Keywords: DLBCL; chemotherapy; immunotherapy; lymphomas.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Prednisone / therapeutic use
Randomized Controlled Trials as Topic
Rituximab / therapeutic use
Standard of Care*
Treatment Outcome
Vincristine / therapeutic use

Substances

Cyclophosphamide
Doxorubicin
Prednisone
Rituximab
Vincristine
R-CHOP protocol

Abstract

MeSH terms

Substances

Grants and funding